BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32227635)

  • 1. Current applications of molecular testing on body cavity fluids.
    Pinto D; Schmitt F
    Diagn Cytopathol; 2020 Sep; 48(9):840-851. PubMed ID: 32227635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proceedings of the American Society of Cytopathology companion session at the 2019 United States and Canadian Academy of Pathology Annual meeting, part 2: effusion cytology with focus on theranostics and diagnosis of malignant mesothelioma.
    Siddiqui MT; Schmitt F; Churg A
    J Am Soc Cytopathol; 2019; 8(6):352-361. PubMed ID: 31495751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology.
    Chevrier M; Monaco SE; Jerome JA; Galateau-Salle F; Churg A; Dacic S
    Cancer Cytopathol; 2020 Dec; 128(12):939-947. PubMed ID: 32678499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serous effusions in malignant lymphomas: a review.
    Das DK
    Diagn Cytopathol; 2006 May; 34(5):335-47. PubMed ID: 16604559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted deep sequencing of cell-free DNA in serous body cavity fluids with malignant, suspicious, and benign cytology.
    Yang SR; Mooney KL; Libiran P; Jones CD; Joshi R; Lau HD; Stehr H; Berry GJ; Zehnder JL; Long SR; Kong CS; Kunder CA
    Cancer Cytopathol; 2020 Jan; 128(1):43-56. PubMed ID: 31751001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining.
    Mansour MSI; Seidal T; Mager U; Baigi A; Dobra K; Dejmek A
    Cancer Cytopathol; 2017 Dec; 125(12):908-917. PubMed ID: 28922567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small orangiophilic squamous-like cells: an underrecognized and useful morphological feature for the diagnosis of malignant mesothelioma in pleural effusion cytology.
    Chen L; Caldero SG; Gmitro S; Smith ML; De Petris G; Zarka MA
    Cancer Cytopathol; 2014 Jan; 122(1):70-5. PubMed ID: 23983174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens.
    Berg KB; Churg AM; Cheung S; Dacic S
    Cancer Cytopathol; 2020 Feb; 128(2):126-132. PubMed ID: 31821740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.
    Hwang HC; Sheffield BS; Rodriguez S; Thompson K; Tse CH; Gown AM; Churg A
    Am J Surg Pathol; 2016 Jan; 40(1):120-6. PubMed ID: 26448191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of ALK rearrangements in malignant pleural effusion cell blocks from patients with advanced non-small cell lung cancer: a comparison of Ventana immunohistochemistry and fluorescence in situ hybridization.
    Wang W; Tang Y; Li J; Jiang L; Jiang Y; Su X
    Cancer Cytopathol; 2015 Feb; 123(2):117-22. PubMed ID: 25529354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions.
    Passebosc-Faure K; Li G; Lambert C; Cottier M; Gentil-Perret A; Fournel P; Pérol M; Genin C
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6862-7. PubMed ID: 16203775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples.
    Zou Y; Xu L; Tang Q; You Q; Wang X; Ding W; Zhao J; Ren G
    BMC Cancer; 2020 Apr; 20(1):344. PubMed ID: 32321471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted deep sequencing of effusion cytology samples is feasible, informs spatiotemporal tumor evolution, and has clinical and diagnostic utility.
    Leichsenring J; Volckmar AL; Kirchner M; Kazdal D; Kriegsmann M; Stögbauer F; Bockmayr T; Klauschen F; Herth FJF; Penzel R; Warth A; Schirmacher P; Endris V; Stenzinger A
    Genes Chromosomes Cancer; 2018 Feb; 57(2):70-79. PubMed ID: 29044880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.
    Cappellesso R; Galasso M; Nicolè L; Dabrilli P; Volinia S; Fassina A
    Cancer Cytopathol; 2017 Aug; 125(8):635-643. PubMed ID: 28449331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using "residual" FNA rinse and body fluid specimens for next-generation sequencing: An institutional experience.
    Wei S; Lieberman D; Morrissette JJ; Baloch ZW; Roth DB; McGrath C
    Cancer Cytopathol; 2016 May; 124(5):324-9. PubMed ID: 26682952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Ancillary Techniques in Fluid Cytology.
    Yu GH; Glaser LJ; Gustafson KS
    Acta Cytol; 2020; 64(1-2):52-62. PubMed ID: 31018204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Young investigator challenge: MicroRNA-21/MicroRNA-126 profiling as a novel tool for the diagnosis of malignant mesothelioma in pleural effusion cytology.
    Cappellesso R; Nicolè L; Caroccia B; Guzzardo V; Ventura L; Fassan M; Fassina A
    Cancer Cytopathol; 2016 Jan; 124(1):28-37. PubMed ID: 26765063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA Ploidy Analysis and Cell Block Immunohistochemistry in the Diagnosis of Malignant Effusions.
    Puri M; Sen R; Gupta M; Kalra R; Bhargava S; Puri K
    Acta Cytol; 2020; 64(3):256-264. PubMed ID: 31466063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of cytological material, pre-analytical procedures and bio-banking in effusion cytopathology.
    Engels M; Michael C; Dobra K; Hjerpe A; Fassina A; Firat P
    Cytopathology; 2019 Jan; 30(1):31-38. PubMed ID: 30430668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.